arrow_back Back to App

US Senate: Access to Medication Abortion Must Be Based on FDA Science.

The US Senate expresses its view that the scientific judgment of the Food and Drug Administration (FDA) confirming the safety and effectiveness of mifepristone (used in medication abortion) must be respected. The goal is to ensure that access to this critical medical care is equitable and based solely on scientific evidence, free from political interference. Maintaining access to this drug is vital for patients, especially given increasing state restrictions that disproportionately affect marginalized communities.
Key points
The Senate calls for policies governing access to medication abortion to be based exclusively on scientific safety and efficacy reviews conducted by the FDA, without interference from state or federal authorities.
Emphasis that mifepristone is safe, effective, and accounts for over half of all abortions in the US; its removal would have a devastating impact on patient health and access to care.
Confirmation that the FDA has the sole authority to approve drugs, and its decisions (including allowing the drug to be dispensed by mail) should be protected from baseless legal claims.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_SRES_510
Sponsor: Sen. Warren, Elizabeth [D-MA]
Process start date: 2023-12-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_SRES_510.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-12-14.

What are the main provisions?

Key points include:

  • The Senate calls for policies governing access to medication abortion to be based exclusively on scientific safety and efficacy reviews conducted by the FDA, without interference from state or federal authorities.
  • Emphasis that mifepristone is safe, effective, and accounts for over half of all abortions in the US; its removal would have a devastating impact on patient health and access to care.
  • Confirmation that the FDA has the sole authority to approve drugs, and its decisions (including allowing the drug to be dispensed by mail) should be protected from baseless legal claims.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Warren, Elizabeth [D-MA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Courts and Law